Fusion Polypeptide Binding VEGF-C and VEGF-D
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current angiogenesis inhibitors used to treat excessive angiogenesis-related diseases, such as cancer, have significant side effects and unsatisfactory efficacy, and there is a need for a more targeted approach that specifically inhibits blood vessel formation without directly acting on cancer cells.
Innovation Solution
A fusion polypeptide that simultaneously binds to angiopoietin 2, VEGF-C, and VEGF-D, acting as a chimeric decoy receptor to inhibit their intracellular signal transduction, thereby inhibiting proliferation and metastasis of cancer cells and lymphangiogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current angiogenesis inhibitors are used to treat excessive angiogenesis-related diseases, then the treatment addresses blood vessel formation, but serious side effects occur and efficacy is unsatisfactory
Solution Approach 1:
The invention segments the anti-angiogenesis function into multiple specialized domains by creating a fusion polypeptide with distinct VEGFR2, VEGFR3, and Tie2 extracellular domains. Each domain specifically targets different receptors involved in angiogenesis and lymphangiogenesis, enabling selective inhibition of pathological processes while preserving normal physiological functions, thereby improving efficacy and reducing side effects
Solution Approach 2:
The fusion polypeptide combines multiple receptor domains (VEGFR2, VEGFR3, Tie2) into a single molecular entity that can simultaneously bind to multiple ligands (VEGF-C, VEGF-D, angiopoietin-2). This multi-functional design allows one agent to address both angiogenesis and lymphangiogenesis pathways, providing comprehensive treatment with improved reliability and reduced need for multiple separate therapies
2Reliability
If VEGF trap is used to inhibit VEGF-A activity, then superior antitumor effect is achieved compared to monoclonal antibodies, but the approach does not simultaneously address VEGF-C and VEGF-D mediated lymphangiogenesis
Solution Approach 1:
The invention merges the VEGF trap concept with lymphangiogenesis inhibition by combining VEGFR2 and VEGFR3 extracellular domains in a single fusion polypeptide. This unified approach simultaneously blocks VEGF-A, VEGF-C, and VEGF-D signaling pathways, addressing both angiogenesis and lymphangiogenesis with one therapeutic agent, thereby improving versatility while maintaining the superior antitumor effect of VEGF trap-based therapies
3Adaptability or versatility
If a fusion polypeptide with multiple receptor domains is designed to bind multiple ligands, then comprehensive inhibition of angiogenesis and lymphangiogenesis is achieved, but the structural complexity increases
Solution Approach 1:
The invention extracts only the essential extracellular domains (Ig-like domains) from the full-length receptors VEGFR2, VEGFR3, and Tie2, omitting the transmembrane and intracellular signaling domains. This extraction creates a simplified fusion polypeptide that retains ligand-binding capability while dramatically reducing structural complexity and facilitating easier production and characterization compared to full-length receptor fusion proteins
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion polypeptide effectively inhibits the migration and proliferation of lymphatic and vascular endothelial cells, providing a potent therapeutic agent for neovascular diseases with improved safety and efficacy compared to existing treatments.
Implementation Method 1
VEGF-C and -D bind VEGFR2 and VEGFR3 which is then activated, thereby performing critical functions for growth, migration and survival of lymphatic endothelial cells
Implementation Method 2
A representative study employs the VEGF trap, which is a water soluble decoy VEGF receptor manufactured by combining domains of VEGFR1 and VEGFR2 on the surface of cells and has high affinity to VEGF-A
Data Source
AI summary
A fusion polypeptide capable of binding simultaneously to angiopoietin 2, VEGF-C and VEGF-D; or capable of binding simultaneously to VEGF-C and VEGF-D, and methods for the preparation and use thereof.